sodium pentobarbital treated with chlorpromazine. The corticotrophic effect of vasopressin in these rats is not potentiated so that the increase in blood pressure per se is not obligatory for the pituitary ACTH release.
Removal of the posterior and intermediate lobes of the pituitary in the rat leads to a reduction in ACTH release in response to neurogenic stress and to abnormal behaviour in a conditioned emotional situation. These abnormalities are counteracted by the treatment of posterior lobectomized rats with long-acting Pitressin or purified lysine vasopressin. These results suggest an effect of vasopressin on higher brain centres and via these centres on ACTH release. Accordingly, vasopressin exerts its stimulatory effect on ACTH release at multiple sites in the body.
Dr W R Greig, Dr J A Boyle, Dr M K Jasani and Dr J D Maxwell (University Departments ofMedicine and Steroid Biochemistry, Royal Infirmary, Glasgow, and the Centrefor Rheumatic Diseases, Glasgow)
Corticotrophin Stimulation Tests
The concentrations of plasma cortisol, measured by the rapid fluorimetric method of Mattingly (1962, J. clin. Path. 15, 374) have been estimated before (basal) and thirty minutes after the intramuscular injection of 250 pg of the synthetic polypeptide Pl-24-corticotrophin (Synacthen) in a total of 242 patients. The results indicate that this procedure, the Synacthen test (Wood et al., 1965, Lancet i, 243; Greig et al., 1966, J. Endocr. 34, 411) , can be a safe and reliable test of adrenocortical function. If subjects without endocrine disorder are tested in the morning, the basal cortisol should not be less than 6 pg/100 ml, the increment should not be less than 7 pg/100 ml and the cortisol thirty minutes after Synacthen should not be less than 18 ,g/100 ml.
From studies on subjects with adrenocortical atrophy either secondary to corticosteroid therapy or to primary failure of the pituitary or adrenal, these criteria for adrenocortical insufficiency were validated. The Synacthen test results in this group of subjects always correlated with those obtained using a four-hour corticotrophin infusion test (Christy et al., 1956 , J. clin. Endocr. 16, 1059 and with the final diagnosis made by other criteria.
Higher than normal results with the Synacthen test consisted of a basal plasma cortisol above 26 pg/100 ml, an increment greater than 25 pg/100 ml and a plasma cortisol thirty minutes after Synacthen, greater than 47 ,ug/100 ml. High results were characteristic of general medical but non-endocrine illness and of gross simple obesity. High results were also found in patients with surgically proven adrenal hyperplasia (producing Cushing's syndrome).
Duplicate Synacthen tests were reproducible, and they may be employed not only in outpatients but in the elderly and infirm, in children and during pregnancy, but more information is required about the latter two groups. 
Some Aspects ofthe Pharmacology ofMetyrapone
Metyrapone is used in the assessment of pituitaryadrenal function, a normal response being dependent on the degree and duration of 11 ,B-hydroxylase inhibition and upon the half-life of cortisol. Complete inhibition, however, of I I -hydroxylase is not obtained with the usual dose regime of 750 mg metyrapone four-hourly by mouth, cortisol secretion rates being nearly normal.
Plasma metyrapone and 1 1-hydroxycorticoid (1 1-OHCS) levels were measured at intervals of thirty minutes, one hour, two hours and four hours after the oral administration of 750 mg metyrapone in 11 subjects. The absorption of the metyrapone was variable, but most subjects showed peak plasma levels at one hour (mean value 370 ,ug/100 ml). Four hours after administration of the metyrapone the plasma levels had fallen (mean value 50 ,ug/100 ml), while plasma 11-OHCS values had risen, after being temporarily depressed.
The half-life of metyrapone was estimated at 20-26 minutes in 3 subjects following the slow intravenous injection of 600 mg metyrapone ditartrate.
In one subject, after ingesting 3 2 g metyrapone in a slow-release base, plasma levels were maintained between 550 and 610 pg/100 ml for four hours but at six hours, had fallen to 35 .g/100 ml.
A study has been done in one subject to determine the relationship between plasma metyrapone levels and percentage suppression of plasma 1 1-OHCS during a period of maximal adrenocortical stimulation with Synacthen. The first day Synacthen was given by intravenous infusion at a rate of 50 pg/h over a period of eight hours, and plasma 11-OHCS levels were estimated twohourly. The second day, metyrapone ditartrate was infused in addition to Synacthen from the third to the eighth hour. Three rates of infusion of metyrapone ditartrate were used: 200 mg during the third and fourth hours, 600 mg. during the fifth and sixth, and 1 2 g during the seventh and eighth. Plasma metyrapone and 1 1-OHCS levels were measured at the end of each two-hour period. It was found that a plasma metyrapone level of 15 jig/100 ml suppressed plasma 1 1-OHCS 25%, 46 ,ug/100 ml suppressed them 72%, and 245 pg/100 ml suppressed them 85 %.
Metyrapone and its metabolites have been extracted from plasma and urine. The predominant metabolite is probably reduced metyrapone, but there are more polar metabolites.
The metyrapone test and the insulin hypoglycwemia test were carried out in 8 patients, 6 of whom had had ablation of the pituitary with yttrium-90 and two of whom had Sheehan's syndrome. It was found that when pituitary destruction was either total or very incomplete the two tests gave comparable results, but that in intermediate cases the metyrapone test appeared to be more sensitive in detecting residual secretion of corticotrophin. The administration of a pyrogen to 40 subjects without endocrine disease resulted in a mean increase in plasma cortisol of 22-1 ,ug/100 ml. Twenty-nine patients with lesions of the pituitary or hypothalamus were studied, and 15 showed a normal response, but in these patients other tests of pituitary-adrenal function, metyrapone and vasopressin, gave a higher proportion of abnormal results. An attempt was made to determine the site of action of pyrogen. The suppression of fever by an antipyretic demonstrated that the febrile and steroid responses were dissociated. Extensive use of a wide variety of drugs known to affect the central nervous system failed to demonstrate any significant depression of the pyrogen response. In particular,morphine failed to affect the pyrogen response whereas it completely suppressed the reaction to vasopressin. These findings, together with other evidence, support the view that pyrogen acts mainly at the level of the pituitary, rather than through the medium of the central nervous system. The assessment of adrenocorticotrophic hormone (ACTH) secretion in man is difficult by direct assay. Indirect methods are therefore used, such as the administration of ACTH and metyrapone, the study of diurnal plasma cortisol values, the response to insulin-induced hypoglycaemia and to lysine-8-vasopressin administration, and the response to the intravenous administration of pyrogen. Each of these methods tests the hypothalamic-pituitary-adrenocortical axis in a different way but it needs to be stressed that, with the exception of ACTH administration, in none of the tests is the precise mechanism of the mode of action generally agreed. It is necessary to understand the limitations of each test, otherwise a fault in diagnosis may be made.
ACTH tests usually use a physiological excess and are carried out to show that the adrenal gland responds normally to its trophic hormone. Our previous work has shown that the synthetic tetracosapeptide Synacthen mimics closely the natural hormone. We have used it widely and found it best to test the sensitivity of the adrenal cortex to the infusion of physiological amounts-of tetracosactide. The intravenous administration of 1 -25 pg for one hour into normal subjects produces a plasma 1 1-hydroxycorticosteroid (11-OHCS) increment of about 13 ,g/100 ml (range 7-2-24-4 pg/100 ml). This is about the same increment of ll-OHCS which is produced by insulin hypoglycemia or by lysine-8-vasopressin administration. It is about two-thirds the increment produced by maximal stimulation by ACTH administered for one hour. When patients with suspected pituitary insufficiency are tested, adrenal insufficiency may be demonstrated by the infusion of submaximal amounts of ACTH whereas the administration of supramaximal amounts may give normal results.
There is in most normal subjects a well-defined diurnal plasma cortisol pattern, the peak levels being found in the morning from about 6 a.m. to 10 a.m., and the lowest levels being found from about midnight to 4 a.m. The diurnal changes in cortisol secretion, however, may vary by some hours from patient to patient so that frequent samples must be taken, which is a practical and helpful procedure with indwelling plastic catheters.
Metyrapone administration as a test of hypopituitarism suffers from a number of disadvantages, mainly because it is difficult to interpret the
